Latest Green Cross Health (NZX:GXH) News

A brutal sell-off in a few small caps sat alongside takeover bids, fresh capital raisings and strong gains in medtech. The week split the market in two: buyers chased clear funding and approval news, while weaker stories sank fast after reopening.

Healthcare shares were driven by regulation, capital and commercial deals this week. The biggest moves came from companies that either moved closer to US sales or raised cash to get there.

Green Cross Health Limited reported a 28% rise in net profit to NZD 20.4 million for FY26, driven by gains in both pharmacy and medical divisions. The company announced a conditional sale of its Medical division to Tend Health for NZD 270 million, aiming to refocus on its core pharmacy business.

Healthcare stocks split into two camps this week. Buyers chased clear commercial wins, while several halted names gave back early excitement once trading resumed. The biggest moves came from a collapse in Opthea, a surge in Control Bionics, and a strong jump in Biome Australia after a margin-boosting manufacturing deal.

Green Cross Health plans to sell its Medical division, The Doctors, for NZ$270 million to Tend Health, refocusing on its pharmacy business. Completion hinges on shareholder approval expected by July 2026.

Speculative small caps drove the week, with Tasman Resources, Solis Minerals and Lithium Energy leading the board after funding, drilling and asset sale updates. At the other end, ASX Ltd and Arafura Rare Earths fell hard as investors reacted to higher costs and fresh equity issuance.

Biotech names led healthcare trading this week, with Noxopharm, Acrux and TruScreen posting the biggest moves after clinical, licensing and expansion updates. Stronger cash flow, fresh capital and new contracts also lifted sentiment across medtech, aged care and healthcare services.

Green Cross Health lifted net profit by 28% to NZD 20.4 million in FY26, driven by stronger medical funding and pharmacy revenue growth, while preparing to launch a new Primary Health Organisation.

Big gains came from contracts, approvals and takeover interest, while several capital raisings and debt deals drew a cooler response. Diagnostics, radiopharma and medtech led the week, with buyers rewarding companies that showed clear sales, supply or hospital access.

Green Cross Health (NZX: GXH) has acknowledged discussions with third parties about a possible sale of its Medical division but emphasised that no transaction is guaranteed. The company remains committed to updating shareholders as the situation develops.